Allopurinol

manufacturers: 9
concepts read: 17
concepts they disagree about: 7

Indications (6)

as stated by Tillomed Laboratories Ltd, Amarox Limited, Aspire Pharma Ltd

Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

as stated by Ipca Laboratories UK Ltd, Aurobindo Pharma - Milpharm Ltd.

Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.
Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

as stated by Flamingo Pharma (UK) Ltd

Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthineguanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.
Allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

as stated by Rosemont Pharmaceuticals Limited

Allopurinol oral suspension is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.
Allopurinol oral suspension is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
Allopurinol oral suspension is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

as stated by Strides Pharma UK Ltd

Allopurinol is indicated to reduce excessive urate levels, where deposition of urate/uric acid has occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis). Allopurinol is also indicated where excessive urate levels are a predictable clinical risk (e.g. cancer chemotherapy).
Excess body urate is frequently idiopathic but may also be found in association with other conditions e.g. neoplastic disease and its treatment; certain enzyme deficiency disorders which lead to overproduction of urate (e.g. Lesch-Nyhan syndrome, glucose-6-phosphate deficiency including glycogen storage disease); chronic renal impairment; diuretic therapy and psoriasis.
Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in patients with raised serum or urinary uric acid, where fluid, dietary and similar measures have failed.
Allopurinol is also indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones associated with adenine phosphoribosyltransferase deficiency.

as stated by Aspen

Zyloric is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). The main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase.
Zyloric is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
Zyloric is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

6 in all

Quick links

Comparing10 productsChoose ↓

Disagreements (7)

scroll for all 10 products →

Concepts	Manufacturers
Concept	Tillomed Laboratories Ltd	Amarox Limited		Ipca Laboratories UK Ltd	Flamingo Pharma (UK) Ltd	Aspire Pharma Ltd	Rosemont Pharmaceuticals Limited	Aurobindo Pharma - Milpharm Ltd.	Strides Pharma UK Ltd	Aspen
	100mg Tablet20/11/2024	100mg Tablets04/04/2025	300mg Tablets04/04/2025	Allopurinol 100mg15/05/2025	100mg Tablets07/02/2025	200mg Tablets22/05/2025	Allopurinol 300mg/5ml Oral Suspension04/03/2026	100mg Tablets20/01/2025	100mg Tablets16/09/2025	100mg TabletsDecember 2024
Benzyl alcohol	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.
Enzyme deficiency	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.
Lactose	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	The label says it can be used, with care.	The label says it can be used, with care.
Sodium and potassium content	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.
Sugar alcohols	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says it can be used, with care.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.
Bleeding risk	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.
Blood disorders	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.	Not found in the sections collected. Not evidence the label omits it.	Not found in the sections collected. Not evidence the label omits it.	The label says another medicine affects it.	The label says another medicine affects it.	The label says another medicine affects it.

Agreements (10)

Storage and shelf life

Shelf life9 differences

Container Blister : 36 months. : 36 monthsFrom 1 manufacturerTillomed Laboratories Ltd
2 yearsFrom 1 manufacturerAmarox Limited
3 years.From 1 manufacturerIpca Laboratories UK Ltd
36 monthsFrom 1 manufacturerFlamingo Pharma (UK) Ltd
36 months.From 1 manufacturerAspire Pharma Ltd
24 months.Use within 30 days of opening the bottle.From 1 manufacturerRosemont Pharmaceuticals Limited
3 years: Tablet containers.2 years: Blister stripsFrom 1 manufacturerAurobindo Pharma - Milpharm Ltd.
4 years – blister packs3 years – polypropylene containersFrom 1 manufacturerStrides Pharma UK Ltd
5 years.From 1 manufacturerAspen

Special precautions for storage8 differences

This medicinal product does not require any special storage conditions.From 2 manufacturersIpca Laboratories UK LtdRosemont Pharmaceuticals Limited
Containers: Do not store above 25°C. Store in the original container.Blister packs: Store in the original package.From 1 manufacturerTillomed Laboratories Ltd
Store below 25°C.From 1 manufacturerAmarox Limited
Store in a cool, dry place below 25°C.From 1 manufacturerFlamingo Pharma (UK) Ltd
Store in the original package in order to protect from light.From 1 manufacturerAspire Pharma Ltd
Tablet containers : Do not store above 25°C. Store in the original container. Keep the container tightly closed.Blister strips: Do not store above 25°C. Store in the original package.From 1 manufacturerAurobindo Pharma - Milpharm Ltd.
Store in a dry place not above room temperature (25°C)From 1 manufacturerStrides Pharma UK Ltd
Do not store above 25°C. Store in the original packaging.From 1 manufacturerAspen

All Allopurinol products (10)

Allopurinol · Interchangeable?